PATIENT LEAFLET IN ACCORDANCE WITH THE PHARMACISTS' REGULATIONS (PREPARATIONS) – 1986
The medicine is dispensed with a doctor's prescription only

CINQAIR®
Concentrate for solution for infusion

Composition:
The active ingredient is reslizumab.
Each 10 mL vial contains:
Reslizumab 100 mg
Each 1 mL contains 10 mg of reslizumab.
Dilution by a healthcare professional is required before administration.
For information regarding inactive ingredients and allergens, see section 2 - "Important information about some ingredients of the medicine" and section 6 - "Additional information".
Read the entire leaflet carefully before using the medicine.
This leaflet contains concise information about the medicine. If you have additional questions, refer to the doctor or the pharmacist.
This medicine has been prescribed for your treatment. Do not pass it on to others. It may harm them even if it seems to you that their medical condition is similar.

A severe allergic reaction (anaphylaxis)
Severe allergic reactions (anaphylaxis) may occur immediately after receiving the Cinqair infusion. These reactions may cause death. Sometimes the allergic reactions do not occur immediately. The medical staff will monitor your condition during and following the Cinqair infusion to identify any sign of an allergic reaction.
Tell the doctor immediately if you experience symptoms that may be associated with an allergic reaction (see section 4 – "Side effects").

1. What is the medicine intended for?
In combination with other medicines, Cinqair is indicated as a maintenance therapy for severe eosinophilic asthma in patients who are 18 years and older.
Cinqair is not indicated:
- As a treatment for other medical conditions caused by eosinophils.
- For the relief of acute bronchospasm or status asthmaticus.

How does Cinqair work:
Medicines like Cinqair decrease the blood eosinophil level. Eosinophils are a type of white blood cells which may worsen asthma.
When Cinqair is given in combination with other medicines for treatment of asthma, it helps to prevent severe asthma attacks (exacerbations) and can improve the quality of breathing.
Therapeutic class: The active ingredient reslizumab belongs to a group of systemic medicines for treatment of obstructive respiratory diseases.

2. Before using the medicine
Do not use this medicine if:

- You are sensitive (allergic) to the active ingredient or to any of the additional components the medicine contains (see section 2 – "Important information about some of the ingredients of the medicine" and section 6 – "Additional information").

Special warnings regarding the use of the medicine:
Before starting treatment with Cinqair, inform the doctor if:
- You are taking oral or inhaled medicines of the corticosteroid group. Do not stop taking the corticosteroids, unless the doctor instructs you to. Stopping the treatment may cause the symptoms treated with corticosteroids to recur.
- You have or have had cancer (malignant tumor).
- You have a parasitic infection (worms).
- You are pregnant or planning to become pregnant. It is unknown whether Cinqair may harm the fetus. Tell your doctor if you become pregnant during treatment with Cinqair.
- You are breastfeeding or are planning to breastfeed. It is not known whether Cinqair passes into breast milk. You and your doctor should decide whether you continue the treatment with Cinqair while breastfeeding. Consult with your doctor regarding the best way to feed your baby if you are taking Cinqair.

Do not stop using other medicines for treatment of asthma, unless the doctor instructs you to.
Children and adolescents:
Cinqair is not indicated for use in children and adolescents under the age of 18.
Drug interactions:
If you are taking or have recently taken other medicines, including non-prescription medicines and nutritional supplements, tell the doctor or the pharmacist.
Pregnancy and breastfeeding:
If you are pregnant, breastfeeding, think you are pregnant or planning to become pregnant, consult with a doctor before using this medicine.
Pregnancy:
There is insufficient information regarding the safety of using Cinqair during pregnancy. Monoclonal antibodies, such as reslizumab, pass across the placenta as the pregnancy progresses. Therefore, the majority of possible effects may occur during the second and third trimester of the pregnancy.
Breastfeeding:
It is unknown whether reslizumab passes into breastmilk and what effect it has on a breastfed baby and on breastmilk production. The developmental and health benefits of breastfeeding should be considered alongside the mother's clinical need for treatment with Cinqair and Cinqair's potential side effects for the breastfed baby.
Important information about some of the ingredients of the medicine:
This medicine contains less than 1 mmol of sodium (23 mg) per vial, and is thus considered to be sodium-free.

3. How should you use the medicine?
Always use the preparation according to the doctor's instructions.
Check with the doctor or pharmacist if you are uncertain about the dosage and how to use the preparation.
The dosage and treatment regimen will be determined only by the doctor.
Do not exceed the recommended dose.
Method of use:
Do not swallow.
Cinqair will be administered to you by the medical staff as an intravenous infusion once every 4 weeks.
The duration of infusion needed in order to receive the required dosage of Cinqair is approximately 20-50 minutes.
If you accidentally receive a higher dosage:
There is no specific treatment for an overdose of Cinqair. If you receive an overdose, the medical staff will monitor your condition and will administer supportive treatment as necessary.
Follow the treatment as recommended by the doctor.
Even if there is an improvement in your health, do not stop treatment with the medicine without consulting the doctor.
Do not take medicines in the dark! Check the label and the dose <u>every time</u> you take the medicine. Wear glasses if you need them.
If you have any other questions regarding use of the medicine, consult the doctor or the pharmacist.

4. Side effects
As with any medicine, using Cinqair may cause side effects in some users. Do not be alarmed when reading the list of side effects. You may not experience any of them.
Severe side effects:
- **Severe allergic reactions (anaphylaxis)**
  Inform the medical staff immediately if you are experiencing any of the following symptoms which may indicate an allergic reaction:
  - Breathing difficulties
  - Pallor
  - Flushing
  - Skin rash (hives)
  - Tingling
  - Swelling of the face, lips, mouth or tongue
  - Symptoms of low blood pressure (fainting, dizziness, light-headedness, confusion, fast heartbeat)
  - Nausea or abdominal discomfort

  Stop the treatment with Cinqair immediately upon the appearance of symptoms of an allergic reaction such as anaphylaxis, and seek adequate medical attention.
- **An abnormal growth of cells or tissues in the body which may or may not be cancer (a malignant tumor)**

The most common side effect is sore throat.
Additional side effects:
- An increase in the levels of the enzyme creatine phosphokinase in the blood
- Muscle pain (myalgia)

If a side effect occurs, if one of the side effects worsens, or if you suffer from a side effect not mentioned in this leaflet, consult your doctor.
Reporting side effects:
Side effects may be reported to the Ministry of Health by clicking on the link "Report side effects due to medicinal treatment" found on the Ministry of Health website homepage (www.health.gov.il), which will direct you to the online form for reporting side effects, or by clicking on the following link: https://sideeffects.health.gov.il

5. How to store the medicine?
Avoid poisoning! This medicine and any other medicine must be kept in a closed place out of the reach and sight of children and/or infants to avoid poisoning. Do not induce vomiting without an explicit instruction from the doctor.
Do not use the medicine after the expiry date (Exp. Date) appearing on the package. The expiry date refers to the last day of that month.
Storage conditions:
Store in the refrigerator (2°-8°C).
Do not freeze. Do not shake.
Store in the original package to protect from light.
Shelf life following dilution:
Use immediately after preparation.
If not used immediately, the diluted solution should be stored in the refrigerator (2°-8°C) or at room temperature (up to 25°C), protected from light, for no more than 16 hours.

6. Additional information
In addition to the active ingredient, the medicine also contains:
Sucrose (low endotoxin), sodium acetate trihydrate, glacial acetic acid, water for injection.
What does the medicine look like and what are the contents of the package:
A clear to somewhat cloudy, colorless to yellowish solution.
Each pack contains:
A single vial of 10 mL of concentrate for solution for infusion.
Name and address of marketing authorization holder and manufacturer:
Teva Israel Ltd.,
124 Dvora HaNevi'a St., Tel Aviv 6944020.
The leaflet was revised in February 2022 in accordance with the Ministry of Health guidelines.
Registration number of the medicine in the National Drug Registry of the Ministry of Health: 159.19.34975.

<u>המידע הבא מיועד לאנשי הצוות הרפואי בלבד:</u>
<u>المعلومات التالية مخصصة لأفراد الطاقم الطبي فقط:</u>
The following information is intended for healthcare professionals only:

DOSAGE AND ADMINISTRATION
Dosing
CINQAIR is for intravenous infusion only. Do not administer as an intravenous push or bolus.
The recommended dosage regimen is 3 mg/kg once every 4 weeks administered by intravenous infusion over 20-50 minutes [see Summary of Product Characteristics: Dosage and Administration (2.2)].
Discontinue the infusion immediately if the patient experiences a severe systemic reaction, including anaphylaxis [see Summary of Product Characteristics: Contraindications (4), Warnings and Precautions (5.1)].
Preparation and Administration Instructions
CINQAIR is provided as a solution in a single-use vial for intravenous infusion only and should be prepared by a healthcare professional using aseptic technique as follows:
Preparation of intravenous infusion
1. Remove CINQAIR from the refrigerator. To minimize foaming, do not shake CINQAIR.
   a. Inspect visually for particulate matter and discoloration prior to administration. CINQAIR solution is clear to slightly hazy/opalescent, colorless to slightly yellow liquid. Since CINQAIR is a protein, proteinaceous particles may be present in the solution that appear as translucent to white, amorphous particulates. Do not administer if discolored or if other foreign particulate matter is present.
2. Withdraw the proper volume of CINQAIR from the vial(s), based on the recommended weight-based dosage. Discard any unused portion.
3. Dispense syringe contents slowly into an infusion bag containing 50 mL of 0.9% Sodium Chloride Injection, USP to minimize foaming of CINQAIR (CINQAIR is compatible with polyvinylchloride (PVC) or polyolefin infusion bags). Gently invert the bag to mix the solution. Do not shake. Do not mix or dilute with other drugs.
4. Administer immediately after preparation. If not used immediately, store diluted solutions of CINQAIR in the refrigerator at 2°C to 8°C or at room temperature up to 25°C, protected from light, for up to 16 hours. The time between preparation of CINQAIR and administration should not exceed 16 hours.

Administration instructions
1. CINQAIR should be administered by a healthcare professional prepared to manage anaphylaxis [see Summary of Product Characteristics: Warnings and Precautions (5.1)].
2. If refrigerated prior to administration, allow the diluted CINQAIR solution to reach room temperature.
3. Use an infusion set with an in-line, low protein-binding filter (pore size of 0.2 micron). CINQAIR is compatible with polyethersulfone (PES), polyvinylidene fluoride (PVDF), nylon, and cellulose acetate in-line infusion filters.
4. Infuse the diluted solution of CINQAIR intravenously, over a 20–50 minute period. Infusion time may vary depending on the total volume to be infused as based upon patient weight.
5. Do not infuse CINQAIR concomitantly in the same intravenous line with other agents. No physical or biochemical compatibility studies have been conducted to evaluate the co-administration of CINQAIR with other agents.
6. Observe the patient over the infusion and for an appropriate period of time following infusion.
7. Upon completion of the infusion, flush the intravenous administration set with 0.9% Sodium Chloride Injection, USP to ensure that all CINQAIR has been administered.